Analyst Reco. Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Real-time Estimate Cboe BZX Other stock markets 02:35:47 2024-05-10 pm EDT			5-day change	1st Jan Change
1.64 ^USD	-2.96%		0.00%	+10.88%

Mar. 13	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	23-08-14	MT
HC Wainwright Adjusts Spero Therapeutics' Price Target to $6 From $7, Maintains Buy Rating	22-09-26	MT
Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line	22-09-22	MT
Fed up!	22-09-22
BOE Raises rates Again, Cuts Inflation Expectations	22-09-22	DJ
Pound Rises Before Likely BOE Rate Rise But Seen Vulnerable	22-09-22	DJ
US Stock Futures Trend Lower Following Fed Rate Increase of 75 Basis Points	22-09-22	MT
UK Poorly Positioned to Cope With Rising Interest Rates	22-09-22	DJ
HC Wainwright Adjusts Spero Therapeutics' Price Target to $7 From $10, Keeps Buy Rating	22-08-15	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT
HC Wainwright Adjusts Spero Therapeutics' Price Target to $10 from $37, Keeps Buy Rating	22-05-23	MT
Berenberg Bank Downgrades Spero Therapeutics to Hold From Buy, Adjusts Price Target to $2 From $44	22-05-20	MT
Cantor Fitzgerald Lowers Spero Therapeutics' Price Target to $5 From $27, Overweight Rating Kept	22-05-17	MT
Cowen Downgrades Spero Therapeutics to Market Perform From Outperform	22-05-04	MT
Evercore ISI Downgrades Spero Therapeutics to In-Line From Outperform, Adjusts Price Target to $2 From $40	22-05-04	MT
HC Wainwright Adjusts Spero Therapeutics' Price Target to $37 From $43, Maintains Buy Rating	22-04-18	MT
HC Wainwright Adjusts Spero Therapeutics' Price Target to $43 From $40, Keeps Buy Rating	22-03-21	MT
Berenberg Bank Adjusts Spero Therapeutics PT to $44 From $47, Maintains Buy Rating	21-11-16	MT
SPERO THERAPEUTICS : Oppenheimer Downgrades Spero Therapeutics to Perform from Outperform	21-10-01	MT
Berenberg US Conference	21-05-18	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Analyst Reco.

Filters